Vaccination News Home Page                                            subscribe Vaccination NewsLetter

http://adc.bmjjournals.com/cgi/content/abstract/archdischild%3b88/5/379

ADC American Academy of Pediatrics
 

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Full Text of this Article
Reprint (PDF) Version of this Article
Email this link to a friend
eLetters: Submit a response to this article
Similar articles found in:
ADC Online
PubMed
PubMed Citation
Search Medline for articles by:
McVernon, J || Moxon, E R
Alert me when:
new articles cite this article
 
Download to Citation Manager
Collections under which this article appears:
Drugs: immunological products and vaccines
Children

Archives of Disease in Childhood 2003;88:379-383
© 2003 BMJ Publishing Group & Royal College of Paediatrics and Child Health

 


ORIGINAL ARTICLE

Immunologic memory in Haemophilus influenzae type b conjugate vaccine failure

J McVernon1, P D R Johnson2, A J Pollard1, M P E Slack3 and E R Moxon1

1 Oxford Vaccine Group, University of Oxford Department of Paediatrics, John Radcliffe Hospital, Oxford, UK
2 Austin and Repatriation Medical Centre, Heidelberg, Victoria, Australia
3 Public Health Laboratory Service Haemophilus Reference Unit, John Radcliffe Hospital, Oxford, UK

Correspondence to:
Dr J McVernon, Oxford Vaccine Group, Department of Paediatrics, Level 4, John Radcliffe Hospital, Headley Way, Headington, Oxford OX3 9DU, UK;
jodie.mcvernon@paediatrics.ox.ac.uk

Aims: To compare the convalescent antibody response to invasive Haemophilus influenzae type b (Hib) disease between conjugate vaccine immunised and unimmunised children, to look for evidence of priming for immunologic memory.

Methods: Unmatched case-control study in the UK and Eire 1992–2001 and Victoria, Australia 1988–1990. A total of 93 children were identified as having invasive Hib disease following three doses of conjugate vaccine in infancy through post licensure surveillance throughout the UK and Eire; 92 unvaccinated children admitted to an Australian paediatric hospital with invasive Hib disease were used as historical controls. Convalescent serum was taken for measurement of Hib antibody concentration, and clinical information relating to potential disease risk factors was collected. The geometric mean concentrations of convalescent Hib antibodies were compared between immunised and unimmunised children, using raw and adjusted data.

Results: Hib conjugate vaccine immunised children had higher serum Hib antibody responses to disease (geometric mean concentration (GMC) 10.81 µg/ml (95% CI 6.62 to 17.66) than unimmunised children (1.06 µg/ml (0.61 to 1.84)) (p < 0.0001). However, following adjustment for the significant confounding influences of age at presentation and timing of serum collection, a difference persisted only in children presenting with meningitis (vaccinated GMC 3.78 µg/ml (2.78 to 5.15); unvaccinated GMC 1.48 µg/ml (0.90 to 2.21); p = 0.003).

Conclusions: Higher antibody responses to invasive Hib disease in vaccinated children with meningitis reflect priming for immunologic memory by the vaccine. Although a majority of children in the UK are protected from Hib disease by immunisation, the relative roles of immunologic memory and other immune mechanisms in conferring protection remain unclear.


Keywords: Haemophilus; immunologic memory; vaccine; conjugate

 

Abbreviations: DTP, diphtheria-tetanus-pertussis; GMC, geometric mean concentration; Hib, Haemophilus influenzae type b; HRU, Haemophilus reference unit; PHLS, Public Health Laboratory Service; PRP; polyribosylribitol phosphate

 


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

 

 

Vaccination News Home Page

 

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.